JHS Svendgaard Laboratories Limited (JHS) AI Stock Analysis

• Market Cap: ₹860.32M
• Dividend Yield: N/A
• Average Volume (3M): 16.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: 16.77%
• EPS Growth: 34.47%
• Country: IN
• Employees: 250
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): -0.02
• Shares Outstanding: 85,603,966
• 10 Day Avg. Volume: 16,348
• 30 Day Avg. Volume: 16,781
• PEG Ratio: -0.01
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 1.06
• P/FCF Ratio: -6.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: ₹10.50 ▲(12.42% Upside)

The score is primarily weighed down by weak financial performance—declining revenue, ongoing losses, and negative free cash flow—despite a strong low-leverage balance sheet. Technicals are neutral-to-weak (negative MACD and trading below longer-term averages), and valuation is constrained by negative earnings and no provided dividend yield.

Positive Factors

Strong balance sheet / low leverage

Very high equity ratio and minimal debt provide durable financial flexibility, enabling the company to fund operations, capex or strategic initiatives without heavy interest burden. Low leverage also supports resilience in downturns and underpins contract-manufacturing credibility.

Contract manufacturing and diversified revenue streams

A dual model of proprietary brands plus contract manufacturing creates stable, multi-channel revenue. Scale manufacturing capability and distributor/retailer partnerships lower unit costs and reduce customer concentration, supporting steady demand and long-term margin potential.

Improving gross profit margin

A notable gross margin improvement indicates better cost control or a favorable product mix, which is a structural lever for restoring profitability. Sustained higher gross margins improve the chance of recovering operating profits if SG&A is managed consistently.

Negative Factors

Sustained losses / negative profitability

Persistent net losses since 2021 signal that core operations fail to generate profit, eroding retained earnings and limiting internal funding for growth. Continued negative margins reduce strategic optionality and increase reliance on external financing for restructuring or investment.

Negative free cash flow and poor cash conversion

Consistent negative free cash flow and weak operating cash conversion constrain the company’s ability to self-fund capex, inventory and payables. Over time this heightens liquidity risk and could force dilutive financing or cutbacks that hamper competitive positioning.

Declining revenue trajectory

A multi-year revenue decline undermines economies of scale and suggests structural demand or market-share issues. Sustained top-line shrinkage pressures fixed-cost absorption and margin recovery, making durable profitability reliant on successful product, pricing or distribution strategy shifts.

JHS Svendgaard Laboratories Limited Business Overview & Revenue Model

Company Description

JHS Svendgaard Laboratories Limited, together with its subsidiaries, manufactures and sells a range of oral and dental products for adults and kids in India. The company offers oral care products, such as toothbrushes, toothpastes, mouthwash products, hand sanitizers, laundry detergents, room fresheners, and denture products under the Dr. Gold and Aquawhite brands. It also provides contract manufacturing services for oral care products of other brands; and operates retail stores at airports. The company also exports its products. JHS Svendgaard Laboratories Limited was founded in 1996 and is based in New Delhi, India.

How the Company Makes Money

JHS generates revenue through multiple streams, primarily by selling its own branded products as well as providing contract manufacturing services for other companies in the oral care sector. The company benefits from economies of scale due to its manufacturing capabilities, which allow it to produce goods at a lower cost. Key revenue streams include sales from proprietary brands, such as various toothpaste and oral hygiene products, and income from contracts with third-party brands looking to leverage JHS's manufacturing expertise. Strategic partnerships with distributors and retail chains also contribute significantly to its earnings, enabling the company to reach a broader customer base and enhance its market presence.

JHS Svendgaard Laboratories Limited Financial Statement Overview

Summary

JHS Svendgaard Laboratories Limited faces significant financial challenges with declining revenue and consistent losses since 2021. Despite a strong equity position and low leverage, the company struggles with profitability and liquidity due to negative cash flows and operational inefficiencies.

Income Statement

The income statement shows a declining trajectory in revenue, with a significant drop from 2020 to 2025. Gross profit margin improved to 33.66% in 2025, indicating better cost management. However, the company has been unprofitable since 2021, with a negative net profit margin of -21.47% in 2025. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows a strong equity position with an equity ratio of 85.83% in 2025, suggesting financial stability. The debt-to-equity ratio remains low at 0.037, which indicates low financial leverage. However, the return on equity is negative due to consistent losses, highlighting profitability issues.

Cash Flow

Cash flow analysis reveals a negative free cash flow in recent years, with a significant deterioration in 2025. The operating cash flow to net income ratio indicates challenges in converting revenue into cash, with a negative ratio in 2025. Despite positive financing cash flow, the company struggles with liquidity due to poor operating performance.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	909.67M	919.97M	698.06M	840.82M	854.91M	1.00B
Gross Profit	303.64M	309.55M	203.55M	165.45M	201.68M	264.03M
EBITDA	-36.20M	-39.92M	33.78M	-163.82M	85.45M	94.57M
Net Income	-180.60M	-197.44M	-40.58M	-175.17M	-40.52M	11.98M
Balance Sheet
Total Assets	0.00	2.01B	1.97B	2.28B	2.22B	2.28B
Cash, Cash Equivalents and Short-Term Investments	195.43M	200.16M	94.56M	386.51M	80.19M	230.38M
Total Debt	0.00	64.58M	51.29M	155.09M	61.82M	70.11M
Total Liabilities	-1.73B	284.41M	271.70M	543.87M	269.46M	299.97M
Stockholders Equity	1.73B	1.73B	1.70B	1.74B	1.86B	1.89B
Cash Flow
Free Cash Flow	0.00	-157.11M	-401.17M	89.43M	-158.75M	36.96M
Operating Cash Flow	0.00	-51.78M	-85.84M	232.86M	-91.36M	120.29M
Investing Cash Flow	0.00	-220.18M	-217.34M	96.77M	-46.97M	-22.25M
Financing Cash Flow	0.00	232.97M	21.74M	-9.00M	-16.72M	103.09M

JHS Svendgaard Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JHS, the sentiment is Negative. The current price of 9.34 is below the 20-day moving average (MA) of 9.98, below the 50-day MA of 10.78, and below the 200-day MA of 12.21, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 47.89 is Neutral, neither overbought nor oversold. The STOCH value of 45.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JHS.

JHS Svendgaard Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GROBTEA	70 Outperform	₹1.16B	-139.68	―	0.30%	-20.04%	-104.83%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
PRITI	52 Neutral	₹726.69M	25.93	―	―	―	―
NAGREEKEXP	51 Neutral	₹774.36M	29.52	―	―	-27.67%	-61.81%
JHS	47 Neutral	₹860.32M	-11.39	―	―	16.77%	34.47%

JHS Svendgaard Laboratories Limited Corporate Events

Exchange Seeks Clarification from JHS Svendgaard on September 2025 Quarterly Results

The stock exchange has sought clarification from JHS Svendgaard Laboratories Limited regarding its financial results for the quarter ended 30 September 2025 under Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements, 2015. The company’s response is still pending, leaving investors and other stakeholders awaiting further information on the queried aspects of its quarterly disclosures.

JHS Svendgaard Laboratories Releases Financial Results for September 2025

JHS Svendgaard Laboratories Limited has announced the publication of its financial results for the quarter and half-year ending September 30, 2025. The results have been published in Financial Express and Jansatta, and are also available on the company’s website. This announcement is part of the company’s compliance with SEBI’s listing regulations, ensuring transparency and timely disclosure of financial performance to stakeholders.